17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)Linong Ji, WEIPING JIA, Jianlin Geng et al.|Diabetes|2019Cited by 5
Rapid quality evaluation of Meconopsis integrifolia (Maxim.) Franch.: Insights from machine learning techniques and environmental factor analysisXi Luo, Jing Sun, Hongmei Li et al.|Industrial Crops and Products|2025Cited by 0